Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP206038.RAJT9MUNQ5qopZHE_NUi0v5U02HpLmHKotCDl6SNEpbXg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP206038.RAJT9MUNQ5qopZHE_NUi0v5U02HpLmHKotCDl6SNEpbXg130_assertion type Assertion NP206038.RAJT9MUNQ5qopZHE_NUi0v5U02HpLmHKotCDl6SNEpbXg130_head.
- NP206038.RAJT9MUNQ5qopZHE_NUi0v5U02HpLmHKotCDl6SNEpbXg130_assertion description "[With a single exception, all primary EOC that overexpressed TF demonstrated high levels of CD46, CD55 and CD59 and regardless of their histology or resistance to chemotherapy, were highly sensitive to IDCC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP206038.RAJT9MUNQ5qopZHE_NUi0v5U02HpLmHKotCDl6SNEpbXg130_provenance.
- NP206038.RAJT9MUNQ5qopZHE_NUi0v5U02HpLmHKotCDl6SNEpbXg130_assertion evidence source_evidence_literature NP206038.RAJT9MUNQ5qopZHE_NUi0v5U02HpLmHKotCDl6SNEpbXg130_provenance.
- NP206038.RAJT9MUNQ5qopZHE_NUi0v5U02HpLmHKotCDl6SNEpbXg130_assertion SIO_000772 21725665 NP206038.RAJT9MUNQ5qopZHE_NUi0v5U02HpLmHKotCDl6SNEpbXg130_provenance.
- NP206038.RAJT9MUNQ5qopZHE_NUi0v5U02HpLmHKotCDl6SNEpbXg130_assertion wasDerivedFrom befree-20140225 NP206038.RAJT9MUNQ5qopZHE_NUi0v5U02HpLmHKotCDl6SNEpbXg130_provenance.
- NP206038.RAJT9MUNQ5qopZHE_NUi0v5U02HpLmHKotCDl6SNEpbXg130_assertion wasGeneratedBy ECO_0000203 NP206038.RAJT9MUNQ5qopZHE_NUi0v5U02HpLmHKotCDl6SNEpbXg130_provenance.